Novel Treatment Strategies for Low-Risk Metastatic Castration-Sensitive Prostate Cancer.

ABSTRACT:

Background

The treatment strategy for metastatic castration-sensitive prostate cancer (mCSPC) has changed significantly in recent years. Based on various guidelines, an upfront androgen receptor signaling inhibitor (ARSI) is the first choice, but in patients of Asian descent, including Japanese patients, there are a certain number of cases in which androgen deprivation therapy (ADT) and CAB are more effective. If patients can be identified who show a marked response to ADT within 12 weeks after the initiation of ADT, which is the inclusion criterion for ARSI clinical trials targeting mCSPC, it would be valuable from an economic standpoint.

Methods

A total of 218 patients with pure prostate adenocarcinoma and treated with ADT at the Kanazawa University Hospital between Januar

SUBMITTER: Iwamoto H 

PROVIDER: S-EPMC11430633 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature